Dallas, TXNCT07300241Now EnrollingIRB Ready

Clear Cell Renal Cell Carcinoma Clinical Trial in Dallas, TX

Access cutting-edge clear cell renal cell carcinoma treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by Neomorph, Inc

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access clear cell renal cell carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clear cell renal cell carcinoma treatment provided free

Apply for This Dallas Location

Check if you qualify for this clear cell renal cell carcinoma clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Clear Cell Renal Cell Carcinoma Study in Dallas

The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.

Sponsor: Neomorph, Inc

Who Can Participate

Inclusion Criteria

Subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).
Subjects must have progressed on or refused standard therapies.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
Estimated life expectancy, in the judgment of the Investigator, of at least 12 weeks.
Formalin-fixed paraffin-embedded (FFPE) tumor tissue, newly obtained or archival, is mandatory for enrollment to the study.
Measurable disease as defined by RECIST v1.1.
Adequate hematologic, hepatic, and renal function defined as:
Hemoglobin ≥10 g/dL,
Absolute neutrophil count ≥1000 cells/µL,
Platelet count ≥100,000/µL,
AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases,
Total bilirubin ≤1.5 × ULN,
Estimated glomerular filtration rate (eGFR) ≥60 mL/min.
Subject can swallow oral medications and does not have a condition that could impair the oral bioavailability of the study drug.
Other inclusion criteria per protocol.

Exclusion Criteria

Non-clear cell predominant RCC histologic subtypes.
Leptomeningeal disease or symptomatic active CNS metastases with exceptions for asymptomatic treated CNS metastases per protocol.
Prior or concurrent malignancies with exceptions per protocol.
History of hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV infection.
Other exclusion criteria per protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT07300241) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clear Cell Renal Cell Carcinoma Treatment Options in Dallas, TX

If you're searching for clear cell renal cell carcinoma treatment options in Dallas, TX, this clinical trial (NCT07300241) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced clear cell renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clear cell renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

More Kidney Cancer Trials in Dallas, TX

See all kidney cancer clinical trials recruiting in Dallas — not just this study.

Browse Kidney Cancer Trials in Dallas →

Browse More Trials by Condition

Kidney Cancer TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX